Shirley Ryan AbilityLab

sralab.org

Total trials

174

Active

71

Phase 3

2

Total enrollment

11,049

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
5-Azacitidine2
Dalfampridine2
Mannitol1
5-Azacytidine 10mg/m^21
5-Azacytidine 20mg/m^21
5-Azacytidine 35mg/m^21
5-Azacytidine 75mg/m^21

Next readouts

  • 2026-03
  • 2026-12
  • 2029-01-01
  • 2030-08-31

Top conditions

  • Stroke52
  • Spinal Cord Injuries24
  • Spinal Cord Injury16
  • Amputation13
  • Multiple Sclerosis8
  • Aphasia8
  • Cerebral Palsy6
  • Healthy6

Frequently asked questions about Shirley Ryan AbilityLab

How many clinical trials does Shirley Ryan AbilityLab have on ClinicalTrials.gov?
Shirley Ryan AbilityLab is listed as the lead sponsor on 174 clinical trials in ClinicalTrials.gov, 71 of which are currently active (recruiting, enrolling, or ongoing).
How many of Shirley Ryan AbilityLab's trials are in Phase 3?
2 of Shirley Ryan AbilityLab's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Shirley Ryan AbilityLab focus on?
Shirley Ryan AbilityLab's most-studied conditions on ClinicalTrials.gov are Stroke, Spinal Cord Injuries, Spinal Cord Injury, Amputation, Multiple Sclerosis.
When are Shirley Ryan AbilityLab's next clinical trial readouts?
Shirley Ryan AbilityLab has 4 upcoming primary-completion readouts tracked here; the soonest is “Double Dose 4-AP on Functional Recovery After Spinal Cord Injury”, expected around 2026-03.